Shengbin H. Shi
Jining, 272029, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Targeting NOTCH1-KEAP1 axis retards chronic liver injury and liver cancer progression via regulating stabilization of NRF2.
Journal: Journal of experimental & clinical cancer research : CR
Published: April 08, 2025
Targeting PYK2 with heterobifunctional T6BP helps mitigate MASLD and MASH-HCC progression.
Journal: Journal of hepatology
Published: July 07, 2023
Combination therapy with dendritic cell loaded-exosomes supplemented with PD-1 inhibition at different time points have superior antitumor effect in hepatocellular carcinoma.
Journal: Cancer immunology, immunotherapy : CII
Published: April 03, 2023
Esophageal submucosal gland duct adenoma: report of a case
Journal: Zhonghua bing li xue za zhi = Chinese journal of pathology
Published: August 18, 2021
Global transcriptome analysis provides new insights in Thellungiella salsuginea stress response.
Journal: Plant biology (Stuttgart, Germany)
Published: October 26, 2018
lncRNA MALAT1, HOTTIP and PVT1 as predictors for predicting the efficacy of GEM based chemotherapy in first-line treatment of pancreatic cancer patients.
Journal: Oncotarget
Published: January 11, 2017
Pemetrexed plus dendritic cells as third-line therapy for metastatic esophageal squamous cell carcinoma.
Journal: OncoTargets and therapy
Published: July 16, 2016
Gemcitabine Plus Vinorelbine as Second-Line Therapy in Patients With Metastatic Esophageal Cancer Previously Treated With Platinum-Based Chemotherapy.
Journal: Oncology research
Published: June 15, 2016
MicroRNA 25, microRNA 145, and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations.
Journal: Translational research : the journal of laboratory and clinical medicine
Published: September 25, 2015
Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma.
Journal: Cancer chemotherapy and pharmacology
Published: May 25, 2015
Pemetrexed plus rituximab as second-line treatment for primary central nervous system lymphoma.
Journal: Medical oncology (Northwood, London, England)
Published: November 09, 2014
Pemetrexed plus dendritic cells as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer who had treatment with TKI.
Journal: Medical oncology (Northwood, London, England)
Published: May 03, 2014
Last Updated: 09/26/2026